Volatile Organic Compounds in Exhaled Breath of Idiopathic Pulmonary Fibrosis for Discrimination from Healthy Subjects

Lung

Volumn 195, Issue 2, 2017, Pages 247-254

  Yamada, Yu ichi ^a,c   Yamada, Gen ^a   Otsuka, Mitsuo ^a   Nishikiori, Hirotaka ^a   Ikeda, Kimiyuki ^a   Umeda, Yasuaki ^a   Ohnishi, Hirofumi ^a   Kuronuma, Koji ^a   Chiba, Hirofumi ^a   Baumbach, Jörg Ingo ^b   Takahashi, Hiroki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b REUTLINGEN UNIVERSITY   (Germany)

^c HAKODATE GORYOUKAKU HOSPITAL   (Japan)

Author keywords

Exhaled breath; Idiopathic pulmonary fibrosis; Ion mobility spectrometer; Multi capillary column; Volatile organic compound

Indexed keywords

ACETOIN; BIOLOGICAL MARKER; ETHYLBENZENE; ISOPRENE; PARA CYMENE; PROTEIN; PROTEIN KL 6; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND;

ADULT; AGED; ARTICLE; BLOOD GAS ANALYSIS; BREATH ANALYSIS; BREATHING MOUTHPIECE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC SPIROMETER; DIAGNOSTIC TEST; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL PNEUMONIA; ION MOBILITY SPECTROMETRY; LUNG FUNCTION TEST; MALE; MULTICAPILLARY COLUMN METHOD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SAMPLER;

EID: 85013996208     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-017-9979-3     Document Type: Article

References (35)

1. King TE Jr, Pardo A, Selman M (2011) Idiopathic pulmonary fibrosis. The Lancet 378:1949–1961
2. Harari S, Caminati A (2010) IPF: new insight on pathogenesis and treatment. Allergy 65:537–553
3. Gross TJ, Hunninghake GW (2001) Idiopathic pulmonary fibrosis. N Engl J Med 345:517–525
4. Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824
5. Rattray NJ, Hamrang Z, Trivedi DK et al (2014) Taking your breath away: metabolomics breathes life in to personalized medicine. Trends Biotechnol 32:538–548
6. Westhoff M, Litterst P, Maddula S et al (2010) Differentiation of chronic obstructive pulmonary disease (COPD) including lung cancer from healthy control group by breath analysis using ion mobility spectrometry. Int J Ion Mobility Spectrum 13:131–139
7. Van Berkel JJ, Dallinga JW, Möller GM et al (2010) A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med 104:557–567
8. Besa V, Teschler H, Kurth I et al (2015) Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects. Int J Chron Obstruct Pulmon Dis 10:399–406
9. Dragonieri S, Schot R, Mertens BJ et al (2007) An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 120:856–862
10. Bunkowski A, Boedeker B, Bader S et al (2009) MCC/IMS signals in human breath related to sarcoidosis: results of a feasibility study using an automated peak finding procedure. J Breath Res 3:046001
11. Westhoff M, Litterst P, Freitag L et al (2007) Ion mobility spectrometry in the diagnosis of sarcoidosis: Results of a feasibility study. J Physiol Pharmacol 58:739–751
12. Phillips M, Cataneo RN, Condos R et al (2007) Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis 87:44–52
13. Phillips M, Basa-Dalay V, Blais J et al (2012) Point-of-care breath test for biomarkers of active pulmonary tuberculosis. Tuberculosis 92:314–320
14. Kamboures MA, Blake DR, Cooper DM et al (2005) Breath sulfides and pulmonary function in cystic fibrosis. Proc Natl Acad Sci USA 102:15762–15767
15. McGrath LT, Patrick R, Mallon P et al (2000) Breath isoprene during acute respiratory exacerbation in cystic fibrosis. Eur Respir J 16:1065–1069
16. Cakir Y, Métraillier L, Baumbach JI et al (2014) Signals in asbestos related diseases in human breath—preliminary results. Int J Ion Mobil Spec 17:87–94
17. Philips M, Cataneo RN, Cummin ARC et al (2003) Detection of lung cancer with volatile markers in the breath. Chest 123:2115–2123
18. Machado RF, Raskowski D, Deffenderfer O et al (2005) Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med 171:1286–1291
19. Westhoff M, Litterst P, Freitag L et al (2009) Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax 64:744–748
20. Darwiche K, Baumbach JI, Sommerwerck U et al (2011) Bronchoscopically obtained volatile biomarkers in lung cancer. Lung 189:445–452
21. Kanoh S, Kobayashi H, Motoyoshi K (2005) Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases. Chest 128:2387–2392
22. Buszewski B, Grzywinski D, Ligor T et al (2013) Detection of volatile organic compounds as biomarkers in breath analysis by different analytical techniques. Bioanalysis 5: 2287–2306
23. Baumbach JI (2009) Ion mobility spectrometry coupled with multi-capillary columns for metabolic profiling of human breath. J Breath Res 3:034001
24. Hauschild AC, Schneider T, Pauling J et al (2012) Computational methods for metabolomic data analysis of ion mobility spectrometry data-reviewing the state of art. Metabolites 2: 733–755
25. Fink T, Baumbach JI, Kreuer S (2014) Ion mobility spectrometry in breath research. J Breath Res 8:027104
26. Cumeras R, Figueras E, Davis CE et al (2015) Review on ion mobility spectrometry. Part 1: current instrumentation. Analyst 140:1376–1390
27. Cumeras R, Figueras E, Davis CE et al (2015) Review on ion mobility spectrometry. Part 2: hyphenated methods and effects of experimental parameters. Analyst 140:1391–1410
28. Foster WM, Jiang L, Stetkiewicz PT et al (1996) Breath isoprene: temporal changes in respiratory output after exposure to ozone. J Appl Physiol 80:706–710
29. Jalali M, Zare Sakhvidi MJ, Bahrami A et al (2016) Oxidative stress biomarkers in exhaled breath of workers exposed to crystalline silica dust by SPME-GC-MS. J Res Health Sci 16:153–161
30. Cheresh P, Kim SJ, Tulasiram S et al (2013) Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta 1832: 1028–1040
31. Chan PC, Haseman JK, Mahleri J et al (1998) Tumor induction in F344/N rats and B6C3F1 mice following inhalation exposure to ethylbenzene. Toxicol Lett 99:23–32
32. Saghir SA, Zhang F, Rick DL et al (2010) In vitro metabolism and covalent binding of ethylbenzene to microsomal protein as a possible mechanism of ethylbenzene-induced mouse lung tumorigenesis. Regul Toxicol Pharmacol 57:129–135
33. Saalberg Y, Wolff M (2016) VOC breath biomarkers in lung cancer. Clin Chim Acta 459:5–9
34. Song G, Qin T, Liu H et al (2010) Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer 67:227–231
35. Xie G, Chen N, Soromou LW et al (2012) p-Cymene protects mice against lipopolysaccharide-induced acute lung injury by inhibiting inflammatory cell activation. Molecules 17:8159–8173